<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00250250</url>
  </required_header>
  <id_info>
    <org_study_id>FE999905 CS002</org_study_id>
    <nct_id>NCT00250250</nct_id>
  </id_info>
  <brief_title>An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG</brief_title>
  <official_title>An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG (Recombinant Somatropin) Administered by ZomaJet Vision X</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Children with growth failure due to inadequate secretion of growth hormone or growth
      retardation due to Turner's syndrome are individually dosed and treated for 12 weeks
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ferring Pharmaceuticals A/S has developed a new ZOMACTON 10 mg formulation. The formulation
      provides a higher concentration and thereby a smaller volume to be administered. ZomaJet
      Vision X is a needle-free injection system. It sends a thin jet of ZOMACTON through the skin
      and into the subcutaneous tissue without the use of a needle. The mode of administration is
      referred to as &quot;transjection&quot;. By use of ZomaJet Vision X, both transjection and
      reconstitution of ZOMACTON 10 mg can be done without using a needle. The rationale of the
      study is to describe the local tolerability of the new ZOMACTON 10 mg administered by ZomaJet
      Vision X.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the local tolerability of an individualised dose of ZOMACTON 10 mg administered by ZomaJet Vision X</measure>
  </primary_outcome>
  <enrollment type="Actual">27</enrollment>
  <condition>Turner's Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ZOMACTON</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subjects between the ages of 3 and 17 years (both inclusive) with growth failure due to
        inadequate secretion of growth hormone or growth retardation due to Turner's syndrome.
        Subjects have for a minimum of 6 months prior to study enrolment been receiving growth
        hormone therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty Hospital Olomouc, Children's Clinic, Endocrinology Outpatient Department, I.P.Pavlova str. 6,</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculty Hospital Kralovske Vinohrady, Children's Clinic, Vinohradska str. 159</name>
      <address>
        <city>Prague 10</city>
        <zip>100 81</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Masaryk Hospital Usti nad Labem, Children's Clinic, Building D2, Endocrinology Outpatient Department, Socialni pece 12a</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>401 13</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre d'Endocrinologie Pediatrique, 25 rue Boudet</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de PÃ©diatrie, Groupe Hospitalier du Havre, 55 bis, rue Gustave Flaubert</name>
      <address>
        <city>Le Havre cedex</city>
        <zip>76083</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vu medisch centrum, Paediatrics, De Boelelaan 1117, PO Box 7057</name>
      <address>
        <city>Amsterdam</city>
        <zip>10007 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2005</study_first_submitted>
  <study_first_submitted_qc>November 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2005</study_first_posted>
  <last_update_submitted>May 19, 2011</last_update_submitted>
  <last_update_submitted_qc>May 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>Clinical Development Support</name_title>
    <organization>Ferring Pharmaceuticals</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Turner Syndrome</mesh_term>
    <mesh_term>Gonadal Dysgenesis</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

